Remove Biopharma Remove Pharma Remove Prescription
article thumbnail

Astellas Pharma CEO Q&a (Part 2): We Have To Have Alternatives for Prescription Medicine Business

MedCity News

In part 2 of our Q&A, Okamura addresses the need for biopharma companies to leverage digital technologies in disease management. The post Astellas Pharma CEO Q&a (Part 2): We Have To Have Alternatives for Prescription Medicine Business appeared first on MedCity News.

article thumbnail

Navigating the Challenges of Biopharma Product Launches: A Blueprint for Success

PM360

Embarking on the journey from product development to market success in the biopharma industry is no small feat. The landscape is highly competitive with new prescription medications launching worldwide each year. However, this journey is fraught with challenges as revealed by an in-depth analysis.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Ipsen beefs up in oncology, buying US biopharma Epizyme

pharmaphorum

The bolt-on deal comes shortly after Ipsen announced plans to sell its consumer health business for around €350 million, leaving it as a pure-play prescription pharma operating in the cancer, rare diseases and neuroscience categories. The post Ipsen beefs up in oncology, buying US biopharma Epizyme appeared first on.

article thumbnail

A Non-Profit Pharma Nabs FDA Nod for Non-Prescription Naloxone Nasal Spray

MedCity News

The FDA approved RiVive, an over-the-counter version of naloxone nasal spray from Harm Reduction Therapeutics. It’s the second such approval from the FDA this year, following an affirmative decision in March for OTC Narcan.

FDA 90
article thumbnail

Access solutions: the missing link that prevents biopharma innovation from reaching patients

pharmaphorum

The clerical overhead of enrolment forms navigated over fax and phone calls fails to deliver on the promise, resulting in lower-than-expected prescription volumes and lacklustre adoption among prescribers. The post Access solutions: the missing link that prevents biopharma innovation from reaching patients appeared first on.

article thumbnail

What Prescription Drug Pricing Can Learn From Value-Based Care Models

MedCity News

As pharma becomes part of the value-based revolution, there are several lessons that can be learned from the ongoing development of value-based care.

article thumbnail

Leading speciality pharmacies in pharma

Pharmaceutical Technology

The speciality drug channel participants, including speciality pharmacies, biopharma companies, and distributors, are transforming their operations with automated and secure data systems and next-generation analytics, which will improve data collection, partner performance and strategy effectiveness. Prescription refill and renewal.